Nepal Gaurav, Yadav Jayant Kumar, Bhandari Siddhartha, Gautam Jeevan, Gajurel Bikram Prasad
Department of Internal Medicine, Maharajgunj Medical Campus, Tribhuvan University Institute of Medicine, Kathmandu, 44600, Nepal.
Department of Neurology, Maharajgunj Medical Campus, Tribhuvan University Institute of Medicine, Kathmandu, 44600, Nepal.
Ann Med Surg (Lond). 2021 Oct 21;72:102969. doi: 10.1016/j.amsu.2021.102969. eCollection 2021 Dec.
Acute ischemic stroke (AIS) patients arriving within a suitable time frame are treated with recanalization therapy i.e. intravenous thrombolysis (IVT) with alteplase and/or mechanical thrombectomy (MT). IVT with alteplase is indicated in AIS patients presenting within 4.5 hours of onset regardless of vascular territory involved. MT is indicated in AIS patients presenting within 24 hours of onset with large vessel occlusion in the anterior circulation. However, MT is ludicrously expensive and requires exorbitant setup, devices, and expertise which is not currently feasible in LMICs. Therefore, in LMICs the only feasible recanalization option left for AIS patients is IVT. The cost of IVT varies across the LMICs, however, most of them cost around 2000-5000 USD. Apart from IVT, patients with AIS often have other significant medical costs including those for neuroimaging, intensive care, and prolonged rehabilitative treatment. In LMICs, these costs can only be afforded by a handful of patients. The majority of the LMICs have health insurance in their infancy and family members of AIS patients opt-out IVT due to the economic burden. In general, the current treatment guidelines for AIS are not very useful in LMICs because of cost-related issues among several other factors. In this editorial, we discuss evidence for alternative treatment strategies that can help tackle the rising epidemic of AIS in poor countries by improvising on existing clinical guidelines and seeking alternative treatment regimens.
在合适时间范围内抵达的急性缺血性卒中(AIS)患者接受再灌注治疗,即使用阿替普酶进行静脉溶栓(IVT)和/或机械取栓(MT)。无论涉及哪个血管区域,在发病4.5小时内就诊的AIS患者都可使用阿替普酶进行IVT。MT适用于前循环大血管闭塞且在发病24小时内就诊的AIS患者。然而,MT极其昂贵,需要高昂的设备、装置和专业技术,这在低收入和中等收入国家(LMICs)目前并不可行。因此,在LMICs中,AIS患者唯一可行的再灌注选择是IVT。IVT的费用在不同的LMICs有所不同,不过大多数费用在2000 - 5000美元左右。除了IVT,AIS患者通常还有其他重大医疗费用,包括神经影像学、重症监护和长期康复治疗的费用。在LMICs中,只有少数患者能够承担这些费用。大多数LMICs的医疗保险尚处于起步阶段,AIS患者的家属因经济负担而选择不进行IVT。总体而言,由于成本相关问题以及其他几个因素,目前的AIS治疗指南在LMICs中并不是非常有用。在这篇社论中,我们讨论了替代治疗策略的证据,这些策略可以通过改进现有临床指南和寻求替代治疗方案,帮助应对贫困国家中不断上升的AIS流行趋势。